No Data
No Data
Japan skiing, Oncolis Bio and others.
A capital and business alliance agreement has been concluded with HUMEDIT, which handles various tests (NIPT/NI-PGS/PCR) such as the issuance of new stocks through third-party allocation (0.07 million3099 shares) and the disposal of treasury shares (0.18 million201 shares). <4584> Kids Bio had a large exercise of subscription rights (with price adjustment clauses) from the 24th, with the number of shares to be delivered starting from the 5th being 0.9 million shares. <4588> Oncolys Bio is conducting clinical research on the next-generation tumor lytic virus OBP-702.
Oncolys BioPharma: Earnings Conference materials
Oncolys BioPharma Reports 2024 Financial Results Highlighting Improved Equity Ratio
Oncolys BioPharma: Summary of financial results for the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Oncolys BioPharma: Notice regarding differences between full-year results and previous fiscal year results
Oncolys BioPharma FY Parent Loss Y1.68B Vs Loss Y1.94B